Intraosseous Pseudoprogression vs. Progression and Recurrence of Clival Chordoma after Proton Radiation Therapy: Case Series

Abstract

Objective To propose a novel entity of possible intraosseous pseudoprogression in clival chordoma following proton radiation therapy (PRT).

Methods A total of 38 consecutive patients who underwent surgical resection followed by PRT for clival chordoma between January 2015 and December 2023 were analyzed retrospectively. Follow-up magnetic resonance imaging (MRI) suggesting recurrence or progression was evaluated for validity. Apparent diffusion coefficient (ADC) and tumor-to-brainstem signal intensity ratio on contrast-enhanced T1-weighted imaging (Rce) were assessed. Pseudoprogression was defined as (1) MRI signs of recurrence or progression with no pathological confirmation despite obtaining a specimen, or (2) MRI signs of recurrence or regression with spontaneous resolution/regression.

Results Of the 11 patients with MRI findings suggestive of recurrence or progression, 3 were diagnosed with recurrence, 5 with progression, and 3 with pseudoprogression. Patients with pseudoprogression were significantly younger than those with progression (p = 0.04), and all were female. The median time to recurrence, progression, and pseudoprogression was 31, 29, and 21 months, respectively. The three pseudoprogression cases were managed with gross-total resection followed by stereotactic radiosurgery, extensive biopsy, and observation, respectively. Although statistical significance was not reached, ADC (p = 0.33) and Rce (p = 0.13) tended to be higher in pseudoprogression cases.

Conclusion After PRT for clival chordoma, intraosseous pseudoprogression should be considered in the differential diagnosis, particularly in relatively young female patients, although the role of ADC and Rce on MRI remains inconclusive. Multidisciplinary teams managing chordomas should take this into account when determining the aggressiveness of treatment in such cases.

Keywords

chordoma - clivus - radiation-induced - necrosis - pseudoprogression

Publikationsverlauf

Eingereicht: 15. November 2024

Angenommen: 12. Februar 2025

Accepted Manuscript online:
14. Februar 2025

Artikel online veröffentlicht:
03. März 2025

• References

• 1 Fletcher C, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5. World Health Organization; 2013
• 2 Stacchiotti S, Sommer J. Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 2015; 16 (02) e71-e83
• 3 Hong S, Laack N, Mahajan A. et al. Analysis of early outcomes of pencil beam proton therapy compared with passive scattering proton therapy for clival chordoma. World Neurosurg 2023; 171: e644-e653
• 4 Young JS, Al-Adli N, Scotford K, Cha S, Berger MS. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. J Neurosurg 2023; 139 (03) 748-759
• 5 Patel TR, McHugh BJ, Bi WL, Minja FJ, Knisely JP, Chiang VL. A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases. AJNR Am J Neuroradiol 2011; 32 (10) 1885-1892
• 6 Korchi AM, Garibotto V, Lovblad KO, Haller S, Weber DC. Radiologic patterns of necrosis after proton therapy of skull base tumors. Can J Neurol Sci 2013; 40 (06) 800-806
• 7 Takahashi M, Mizumoto M, Oshiro Y. et al. Risk factors for radiation necrosis and local recurrence after proton beam therapy for skull base chordoma or chondrosarcoma. Cancers (Basel) 2023; 15 (23) 5687
• 8 Hong S, Laack N, Mahajan A. et al. Mayo clinic clival chordoma case series: impact of endoscopic training on clinical care. Cancers (Basel) 2022; 14 (20) 5104
• 9 Hong S, Shinya Y, Mahajan A. et al. Long-term outcome of primary clival chordomas: a single-center retrospective study with an emphasis on the timing of recurrences based on the primary treatment. Neurosurg Focus 2024; 56 (05) E4
• 10 Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in neuro-oncology clinical trials. J Clin Oncol 2017; 35 (21) 2439-2449
• 11 Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9 (05) 453-461
• 12 Taal W, Brandsma D, de Bruin HG. et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008; 113 (02) 405-410
• 13 Abbasi AW, Westerlaan HE, Holtman GA, Aden KM, van Laar PJ, van der Hoorn A. Incidence of tumour progression and pseudoprogression in high-grade gliomas: a systematic review and meta-analysis. Clin Neuroradiol 2018; 28 (03) 401-411
• 14 Kumar AJ, Leeds NE, Fuller GN. et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000; 217 (02) 377-384
• 15 Lampert PW, Davis RL. Delayed effects of radiation on the human central nervous system; “early” and “late” delayed reactions. Neurology 1964; 14: 912-917
• 16 Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 2015; 36 (05) 877-885
• 17 Hasegawa H, Shin M, Niwa R. et al. Revisitation of imaging features of skull base chondrosarcoma in comparison to chordoma. J Neurooncol 2022; 159 (03) 581-590
• 18 Hu YS, Lee CC, Wu CA. et al. Magnetic resonance imaging signal characteristics associated with prognosis of skull base chordoma after gamma knife radiosurgery. J Neurooncol 2023; 161 (01) 45-56